Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001889772 | SCV002143655 | uncertain significance | Familial cancer of breast; Fanconi anemia complementation group J | 2022-10-26 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BRIP1 protein function. ClinVar contains an entry for this variant (Variation ID: 1376897). This variant has not been reported in the literature in individuals affected with BRIP1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 182 of the BRIP1 protein (p.Asn182Ser). |
| Ambry Genetics | RCV004041088 | SCV005029282 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-10-01 | criteria provided, single submitter | clinical testing | The p.N182S variant (also known as c.545A>G), located in coding exon 5 of the BRIP1 gene, results from an A to G substitution at nucleotide position 545. The asparagine at codon 182 is replaced by serine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |